Revium Rx.
RVRC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RVRC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RVRC
Revium Rx (RVRC) is a pre-revenue biopharmaceutical company developing lipid-based therapies through its subsidiary LipoVation Ltd, with lead programs in Nano-Mupirocin, Nano-Candesartan, and an LPLT vaccine platform, and is currently advancing toward initial clinical development while addressing scientific and contractual challenges.
Key risk: Limited cash runway
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Revium Rx..
Revium Rx (RVRC) is a pre-revenue biopharmaceutical company developing lipid-based therapies through its subsidiary LipoVation Ltd, with lead programs in Nano-Mupirocin, Nano-Candesartan, and an LPLT vaccine platform, and is currently advancing toward initial clinical development while addressing scientific and contractual challenges.
- Revium Rx focuses on next-generation lipid-based therapies via its subsidiary LipoVation Ltd, acquired in July 2024 [sec_mda · as of 2026-03-31].
- Lead program Nano-Mupirocin is advancing toward initial clinical development, pending completion of stability studies and regulatory clearance [sec_mda · as of 2026-08-13].
- Nano-Candesartan program is delayed due to unresolved contractual matters with Yissum Research Development Company [sec_mda · as of 2026-05-14].
- LPLT vaccine program (SARS-CoV-2 challenge study) results are pending due to study execution issues [sec_mda · as of 2026-08-13].
- As of 2026-06-30, the company had cash & equivalents of $0.8M, net income of -$0.7M, and shareholders' equity of $6.9M [latest reported financials].
What works
- The Nano-Mupirocin program is progressing toward clinical trials, with stability studies and regulatory strategy underway [sec_mda · as of 2026-08-13].
- The company's lipid-based platform targets large markets, including the global anticancer therapeutics market valued at ~$222.71 billion in 2023 [sec · filed 2025-02-14].
- Revium Rx has a clear near-term objective to initiate clinical trials for Nano-Mupirocin where authorized [sec_mda · as of 2026-08-13].
What to weigh
- The company has not generated any revenue from product sales and does not expect to in the near term [sec_mda · as of 2026-05-14].
- Nano-Candesartan program is delayed due to a contractual dispute with Yissum, with no resolution timeline [sec_mda · as of 2026-05-14].
- LPLT vaccine program results are pending due to study execution issues, and related development activities remain paused [sec_mda · as of 2026-08-13].
- Cash & equivalents of $0.8M as of 2026-06-30 are limited, and the company will require additional capital to fund operations [sec_mda · as of 2026-05-14].
From the filings
Quoted directly from source documents.
The company is developing next-generation, lipid-based therapies through its subsidiary LipoVation Ltd.
“Through its subsidiary LipoVation Ltd, the Company is developing next-generation, lipid-based therapies to address some of the most pressing challenges in medicine.”
SEC MD&A · March 31, 2026
Nano-Mupirocin program is advancing toward initial clinical development.
“advancing the Nano-Mupirocin program into initial clinical development, subject to completion of ongoing analyses and regulatory requirements.”
SEC MD&A · August 13, 2026
Nano-Candesartan program is delayed due to contractual issues with Yissum.
“The reason for the delay is that the planned large-animal safety study has not commenced pending receipt of a final scientific report that we believe is required under our agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.”
SEC MD&A · May 14, 2026
The company has not generated any revenue from product sales.
“We have not generated any revenue from product sales to date, and do not expect to generate revenues in the near term.”
SEC MD&A · May 14, 2026
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash & equivalents of $0.8M as of 2026-06-30 may not sustain operations without additional financing [latest reported financials].
- Contractual dispute delays program — Nano-Candesartan program is stalled due to unresolved contractual matters with Yissum [sec_mda · as of 2026-05-14].
- Clinical development uncertainty — All programs are pre-clinical or early-stage, with no guarantee of successful clinical outcomes or regulatory approval [sec_mda · as of 2026-08-13].
- LPLT study execution issues — SARS-CoV-2 challenge study results are delayed due to execution problems, pausing related activities [sec_mda · as of 2026-08-13].
What to watch
- Completion of Nano-Mupirocin stability studies and initiation of clinical trials [sec_mda · as of 2026-08-13].
- Resolution of contractual dispute with Yissum regarding Nano-Candesartan program [sec_mda · as of 2026-05-14].
- Receipt of results from the LPLT SARS-CoV-2 challenge study [sec_mda · as of 2026-08-13].
- Company's ability to secure additional capital to fund operations [sec_mda · as of 2026-05-14].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Revium Rx. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Revium Rx. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
5.5 months
D/E 0.29 · 0% dilution
Lead: Preclinical
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for Revium Rx.?
Revium Rx (RVRC) is a pre-revenue biopharmaceutical company developing lipid-based therapies through its subsidiary LipoVation Ltd, with lead programs in Nano-Mupirocin, Nano-Candesartan, and an LPLT vaccine platform, and is currently advancing toward initial clinical development while addressing scientific and contractual challenges.
What is Revium Rx.'s lead drug candidate?
Revium Rx.'s most advanced tracked candidate is nano-candesartan (Preclinical) for pancreatic cancer.
Who is the CEO of Revium Rx.?
Mr. Amir Avraham CPA is the chief executive officer of Revium Rx. (RVRC).
Where is Revium Rx. headquartered?
Revium Rx. (RVRC) is headquartered in Herzliya, Israel.
What therapeutic areas does Revium Rx. focus on?
Revium Rx. develops therapies across Oncology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.